Related coverage linked through entity extraction aliases.
Mar 26, 2026
The FDA has approved Agilent's PD-L1 IHC 22C3 pharmDx as a companion diagnostic for identifying esophageal cancer patients eligible for Merck's KEYTRUDA immunotherapy. This marks the eighth FDA-approved indication for this diagnostic test with KEYTRUDA. The test helps identify patients whose tumors express PD-L1 for potential treatment with the anti-PD-1 therapy.
Feb 24, 2026
The global oncology precision medicine market is projected to grow from $190.50 billion in 2026 to $366.53 billion by 2033 at a 9.8% CAGR, while the cancer biomarker testing market is expected to reach $96.53 billion by 2033 at a 12.6% CAGR.
Feb 17, 2026
Merck secures regulatory approvals for Keytruda in ovarian cancer and subcutaneous formulation in Canada, while launching AI-driven drug discovery partnership with Mayo Clinic targeting high-need therapeutic areas.
